Open Orphan PLC (AIM:ORPH, OTC:OPORF)'s (Open Orphan PLC (AIM:ORPH, OTC:OPORF), Open Orphan PLC (AIM:ORPH, OTC:OPORF)) Cathal Friels talks about the business opportunities after news that researchers at its hVIVO subsidiary inoculated the first group of volunteers as part of its first controlled human malaria infection challenge study.
Following the completion of the evaluation, hVIVO will then be able to sign human challenge study contracts to assess the efficacy of new antimalarial drugs and vaccines.
The study will take place at hVIVO’s facilities in London. Work will be completed in the first quarter with a data read-out at some point in the following three months.